# RNN 2nd Gen Model AmerisourceBergen Corporation Drugs, proprietaries, & sundries

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
72.40%Expected margin
50.00% successful of 6 deals
$ 118.38 Last close price
at 18-oct-2021


Model's trade recommendations No return for period yet

-1.14% Annual return

$20.25B Market Cap

β 1.04  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return
52wk Range
Sortino ratio -0.39
Sharpe ratio -0.34
Norm. RMSE 73.93%
Downside risk 3.60%
Volatility 0.00%
  • 1.52 (1.65%) Div (Yield)
  • BUY Analysts consensus recommendation

AmerisourceBergen Corporation provides pharmaceutical services. It distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers. The Company also provides pharmacy services to certain specialty drug patients. AmerisourceBergen Corporation is based in Chesterbrook, Pennsylvania.

Industry sector: Medical

Sector classification: Drugs, proprietaries, & sundries

Deep Learning based analysis and prediction model for AmerisourceBergen Corporation (ABC) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for ABC model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ABC.

Model is being retrained on a regular basis.

Float 160M
P/E 14.75
Shares Outstanding 220M
% Held by Insiders 27.30%
% Held by Institutions 67.10%
EPS (last reported FY) $5.88
EPS (last reported Q) $1.94
EPS, estimated (last reported Q) $1.83
Total revenues $153 B
Net income $0 B